Summer Xia

438 total citations · 2 hit papers
11 papers, 234 citations indexed

About

Summer Xia is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Summer Xia has authored 11 papers receiving a total of 234 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Summer Xia's work include Lung Cancer Treatments and Mutations (5 papers), Autoimmune Bullous Skin Diseases (3 papers) and HER2/EGFR in Cancer Research (3 papers). Summer Xia is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Autoimmune Bullous Skin Diseases (3 papers) and HER2/EGFR in Cancer Research (3 papers). Summer Xia collaborates with scholars based in China, United States and Japan. Summer Xia's co-authors include Koremasa Hayama, K. Lheritier, Vipul Jain, Ana M. Giménez‐Arnau, Adam Reich, Pauline Walsh, Sibylle Haemmerle, William Berger, Marcus Maurer and I. Gilloteau and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Summer Xia

10 papers receiving 231 citations

Hit Papers

Remibrutinib, a novel BTK inhibitor, demonstrates promisi... 2022 2026 2023 2024 2022 2024 25 50 75 100
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria
    2022 100 citations Marcus Maurer, William Berger et al. Journal of Allergy and Clinical Immunology profile →
  2. The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial
    2024 45 citations Qiao Li, Qingyuan Zhang et al. Nature Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Summer Xia China 5 108 84 62 60 55 11 234
Donald McNeil United States 4 106 1.0× 153 1.8× 121 2.0× 21 0.3× 335 6.1× 14 415
Cecilia Arana Yi United States 8 28 0.3× 35 0.4× 24 0.4× 11 0.2× 71 1.3× 21 210
Martina Teichmann Germany 3 180 1.7× 59 0.7× 59 1.0× 13 0.2× 26 0.5× 4 225
Tihana Rumboldt United States 8 43 0.4× 19 0.2× 129 2.1× 81 1.4× 7 0.1× 10 284
B.F. Leeb Austria 6 132 1.2× 229 2.7× 25 0.4× 16 0.3× 10 0.2× 8 317
S. Le Burel France 4 59 0.5× 25 0.3× 47 0.8× 6 0.1× 114 2.1× 7 344
Mona Amini‐Adlé France 9 48 0.4× 11 0.1× 21 0.3× 41 0.7× 18 0.3× 30 275
Jiadai Xu China 11 54 0.5× 9 0.1× 27 0.4× 33 0.6× 23 0.4× 43 288
Yehuda E. Deutsch United States 8 52 0.5× 7 0.1× 44 0.7× 19 0.3× 27 0.5× 23 242
Aikaterini Parasi Greece 9 16 0.1× 16 0.2× 68 1.1× 7 0.1× 59 1.1× 13 228

Countries citing papers authored by Summer Xia

Since Specialization
Citations

This map shows the geographic impact of Summer Xia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Summer Xia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Summer Xia more than expected).

Fields of papers citing papers by Summer Xia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Summer Xia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Summer Xia. The network helps show where Summer Xia may publish in the future.

Co-authorship network of co-authors of Summer Xia

This figure shows the co-authorship network connecting the top 25 collaborators of Summer Xia. A scholar is included among the top collaborators of Summer Xia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Summer Xia. Summer Xia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Goldman, Jonathan W., Shun Lü, Jair Bar, et al.. (2025). LUMINOSITY, a phase 2 study of telisotuzumab vedotin in patients with c-Met protein–overexpressing non-squamous EGFR -wildtype advanced NSCLC: Efficacy outcomes by prior therapy.. Journal of Clinical Oncology. 43(16_suppl). 8618–8618. 1 indexed citations
2.
3.
Lü, Shun, Jonathan W. Goldman, Junko Tanizaki, et al.. (2024). A phase 3 global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met 0verexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01).. Journal of Clinical Oncology. 42(16_suppl). TPS8656–TPS8656. 4 indexed citations
4.
Li, Qiao, Qingyuan Zhang, Quchang Ouyang, et al.. (2024). The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial. Nature Communications. 15(1). 1015–1015. 45 indexed citations breakdown →
5.
Camidge, David Ross, Jair Bar, Hidehito Horinouchi, et al.. (2024). Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial.. Journal of Clinical Oncology. 42(16_suppl). 103–103. 8 indexed citations
6.
Zhang, Qingyuan, Jingxuan Wang, Quchang Ouyang, et al.. (2023). Abstract PD18-08: Efficacy and safety results of KN026, a HER2-targeted bispecific antibody combined with docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer. Cancer Research. 83(5_Supplement). PD18–8. 1 indexed citations
7.
8.
Maurer, Marcus, William Berger, Ana M. Giménez‐Arnau, et al.. (2022). Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology. 150(6). 1498–1506.e2. 100 indexed citations breakdown →
9.
Gong, Jifang, Lei Chen, Meili Sun, et al.. (2022). Abstract CT542: Preliminary safety and efficacy results of KN046 in combination with KN026 in patients with locally advanced unresectable or metastatic HER2-positive solid cancer. Cancer Research. 82(12_Supplement). CT542–CT542. 3 indexed citations
10.
Maurer, Marcus, William Berger, Ana M. Giménez‐Arnau, et al.. (2021). Remibrutinib (LOU064) Versus Placebo in Patients with Chronic Spontaneous Urticaria: A Randomised, Double-Blind, Phase 2b Dose-Finding Study. SSRN Electronic Journal. 1 indexed citations
11.
Bagel, Jerry, John K Nia, Peter W. Hashim, et al.. (2018). Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results). Dermatology and Therapy. 8(4). 571–579. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Donald McNeil Breakdown of academic impact, for papers by Cecilia Arana Yi Breakdown of academic impact, for papers by Martina Teichmann Breakdown of academic impact, for papers by Tihana Rumboldt Breakdown of academic impact, for papers by B.F. Leeb Breakdown of academic impact, for papers by S. Le Burel Breakdown of academic impact, for papers by Mona Amini‐Adlé Breakdown of academic impact, for papers by Jiadai Xu Breakdown of academic impact, for papers by Yehuda E. Deutsch Breakdown of academic impact, for papers by Aikaterini Parasi
Rankless by CCL
2026